Palbociclib for the treatment of sarcoma

Share This Post

Sarcoma, which occurs in young people and is a malignant tumor derived from mesenchymal tissue (including connective tissue and muscle). Sarcomas are highly malignant and develop rapidly! Common sarcomas include osteosarcoma, leiomyosarcoma, lymphosarcoma, and synovial sarcoma. Leiomyoma, lymphosarcoma, and synovial sarcoma may develop blood metastases at an early stage.  

The preferred method of sarcoma is surgery. In order to seek a radical cure, domestic doctors usually require patients to have their limbs amputated. However, it is currently difficult to treat unresectable or advanced liposarcoma and leiomyosarcoma that occur behind the peritoneum and have large tumors. Hospitals at home and abroad tend to retain most of the limbs and then perform radiotherapy.

Sarcoma is not sensitive to chemotherapy drugs! The efficiency of local radiotherapy is also poor, but once the lung metastases are less effective.

Palbociclib capsule is a highly selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. It is also the first breast cancer immunotherapy inhibitor to be approved by the US FDA. Palbociclib capsules are targeted drugs for the treatment of sarcoma.

How Palbociclib works: All living cells undergo cell division, and Palbociclib can effectively inhibit the cell division process, and combining Palbociclib with other anti-cancer therapies such as endocrine therapy, chemotherapy, and other targeted therapies can treat many types of cancer Produce a powerful healing effect.

Targeted therapy can use a variety of drugs and other interventions to accurately identify and attack cancer cells without harming normal cells. Dr. Peter J. O’Dwyer said that in addition to neutrophils, Palbociclib has a The effect of cells is also small, and the drug can effectively inhibit the growth of tumors in tumors. As we discover new functions of target CDK4 / 6, we may develop new drug combinations as emerging anti-cancer agents.

According to the research results and early clinical trial results published by scientists at the University of Pennsylvania in the journal JAMA Oncology, the results of phase 2 clinical trials of 29 sarcoma patients show that the drug Palbociclib can achieve a median progression-free survival of 66% of patients 12 weeks. Palbociclib is effective in the treatment of sarcoma and can prolong the progression-free survival of patients.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه
Start chat
Need help with cancer treatment?
Scan the code
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy